Linked Life Data

11310918

Source:http://linkedlifedata.com/resource/pubmed/id/11310918

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2001-4-19
pubmed:abstractText
We examined the clinical characteristics and prognosis in six patients with familial von Hippel-Lindau (VHL) disease and seven with sporadic hemangioblastomas. The expression of vascular endothelial growth factor (VEGF), p53 protein, and proliferative potential with Ki67 monoclonal antibody (MIB-1) was compared using immunohistochemical methods between sporadic and VHL disease-associated hemangioblastomas. Patients with sporadic CNS hemangioblastomas were treated by total removal of the tumors, and they had a good long-term prognosis without neurological deficits on recurrence. However, patients with familial VHL disease often had multiple hemangioblastomas in the CNS and visceral tumors. Even if total removal of CNS hemangioblastomas in patients with VHL disease was performed initially, small multiple hemangioblastomas recurred during long-term follow-up in areas remote from the primary region resected by surgery. All of the hemangioblastomas displayed extensive overexpression of VEGF protein, with moderate to marked proliferation of blood vessels. The MIB-1 indices showed low values of 0.8% as the mean, with a range of 0.03%-2.1% for all the hemangioblastomas. None of the hemangioblastomas expressed p53 protein. The hemangioblastomas in patients with VHL disease were multiple in the CNS and were combined with visceral tumors. Patients with VHL disease had a poor long-term prognosis, in contrast to those with sporadic hemangioblastomas. The immunohistochemical findings for VEGF protein, p53 protein, and MIB-1 did not differ significantly between the sporadic and VHL disease-associated hemangioblastomas.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1433-7398
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-20
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:11310918-Adolescent, pubmed-meshheading:11310918-Adult, pubmed-meshheading:11310918-Antibodies, Monoclonal, pubmed-meshheading:11310918-Antigens, Nuclear, pubmed-meshheading:11310918-Biological Markers, pubmed-meshheading:11310918-Brain Neoplasms, pubmed-meshheading:11310918-Child, pubmed-meshheading:11310918-Endothelial Growth Factors, pubmed-meshheading:11310918-Female, pubmed-meshheading:11310918-Hemangioblastoma, pubmed-meshheading:11310918-Humans, pubmed-meshheading:11310918-Immunohistochemistry, pubmed-meshheading:11310918-Ki-67 Antigen, pubmed-meshheading:11310918-Lymphokines, pubmed-meshheading:11310918-Magnetic Resonance Imaging, pubmed-meshheading:11310918-Male, pubmed-meshheading:11310918-Middle Aged, pubmed-meshheading:11310918-Nuclear Proteins, pubmed-meshheading:11310918-Pedigree, pubmed-meshheading:11310918-Tumor Suppressor Protein p53, pubmed-meshheading:11310918-Vascular Endothelial Growth Factor A, pubmed-meshheading:11310918-Vascular Endothelial Growth Factors, pubmed-meshheading:11310918-Vision Disorders, pubmed-meshheading:11310918-von Hippel-Lindau Disease
pubmed:year
2000
pubmed:articleTitle
Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas.
pubmed:affiliation
Department of Neurosurgery, Nihon University Surugadai Hospital, Tokyo, Japan. nougeka@med.nihon-u.ac.jp
pubmed:publicationType
Journal Article